
Product Data Sheet

Product Name: Entacapone sodium salt

Cat. No.: GC18091

Chemical Properties

Cas. No. 1047659-02-8

Chemical Name sodium (E)-5-(2-cyano-3-(diethylamino)-3-oxoprop-1-en-1-yl)-2-hydroxy-3-nitrophenolate

SMILES CCN(C/C(C#N)=C([H])/C1=CC(N(=O)=O)=C(O)C([O-])=C1)=O)CC.[Na+]

Formula $C_{14}H_{14}N_3NaO_5$ M.Wt 327.27

Solubility Soluble in DMSO Storage Store at -20°C

General tips For obtaining a higher solubility, please warm the tube at 37 °C and shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.

Shipping Condition Evaluation sample solution : ship with blue ice All other available size: ship with RT, or blue ice upon request.

Structure

Background

Entacapone, a nitrocatechol compound, is a selective and reversible inhibitor of catechol-O-methyltransferase (COMT), a Mg²⁺-dependent enzyme involved in the metabolism of catecholamines and catechol compounds, with the half maximal inhibition concentration IC₅₀ and inhibition constant K_i values of 20.1 nM and 10.7 nM respectively [1 & 2].

The nitro group at the position ortho to the hydroxyl group in the chemical structure of entacapone has been identified as a critical component for its potency and ability to inhibit COMT [2].

Entacapone is an FDA-approved COMT inhibitor for use as an adjunct to levodopa therapy in patients' with Parkinson's disease, where it increases both the peripheral and central availability of levodopa [2].

Reference

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

Product Data Sheet

References:

- [1] Forsberg M, Lehtonen M, Heikkinen M, Savolainen J, Järvinen T, Männistö PT. Pharmacokinetics and pharmacodynamics of entacapone and tolcapone after acute and repeated administration: a comparative study in the rat. *J Pharmacol Exp Ther.* 2003 Feb;304(2):498-506.
- [2] Najib J. Entacapone: a catechol-O-methyltransferase inhibitor for the adjunctive treatment of Parkinson's disease. *Clin Ther.* 2001 Jun;23(6):802-32; discussion 771.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA